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doi:10.1016/j.jfma.2011.12.007Neonatal seizures are common and often reflect a severe underlying neurologic dysfunction in
neonates. Phenobarbital remains the mainstay of treatment of neonatal seizures, however,
but it is ineffective in many patients and has adverse profiles in cognition. Furthermore,
gamma-aminobutyric acid is excitatory early in brain development; therefore, treatment of
neonatal seizures with phenobarbital must be cautious. In this review, we highlight the
substantial progress that has been made in animal studies, and translate these results to the
treatment of seizures in human neonates.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Neonatal seizures are defined clinically as abnormal,
stereotyped, paroxysmal alterations in neurological func-
tion, occurring in the first 28 days after birth of a term
neonate or up to 44 weeks’ conceptional age in a preterm
infant.1 The risk of seizures is highest in the neonatal period
(1.8e3.5/1000 live births in the U.S.A.).2e4 In prematuret of Pediatrics, Chang Gung
3 Ta-Pei Road, Niao Sung,
.tw (L.-T. Huang).
ight ª 2012, Elsevier Taiwan LLCinfants, the incidence is higher in those of <30 weeks’
gestation (3.9%) than those of older infants (1.5%).5
Seizures in the neonatal period are common. Neonatal
seizures continue to present a diagnostic and therapeutic
challenge to pediatricians. Electrographically documented
neonatal seizures with or without clinical correlates repre-
sent the most accurate and current concept of neonatal
seizures. Neonatal seizures often reflect a severe underlying
neurologic dysfunction in neonates.
Common etiologies of neonatal seizures
Neonatal seizures can be either symptomatic or idiopathic.
During birth process and early postpartum, hypoxic-ischemic& Formosan Medical Association. All rights reserved.
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metabolic disturbances can be encountered and result in
neonatal seizures. In addition, congenital brain anomalies,
inborn errors of metabolism, and genetic disorders can
lead to neonatal seizures. In human newborns, seizures are
more commonly symptomatic of an underlying brain insult.
Indeed, the most common etiology for neonatal seizures is
hypoxic-ischemic encephalopathy, which affects approxi-
mately one to two of 1000 live births.2e4About two-thirds of
cases of neonatal seizures are caused by hypoxic-ischemic
encephalopathy.6
Table 1 shows common causes, age of onset, and prog-
nosis of neonatal seizures.
Current treatment status of neonatal seizures
It has long been a standard procedure to treat neonatal
seizures with phenobarbital, a gamma-aminobutyric acid
(GABA) receptor agonist that acts by keeping chloride
channels open longer.7 An earlier study demonstrated that
fewer than 50% of the infants treated with either pheno-
barbital or phenytoin responded with electrographic
cessation of seizures, even at high doses.7 A recent survey
among five neonatal intensive care units in the U.S.A. from
2000 to 2003 showed that among the 480 neonates with
seizures, anticonvulsant therapy is initiated in 94% of
neonates with seizures, and that phenobarbital is admin-
istered initially for 82%.8 Phenobarbital remains the main-
stay of treatment of neonatal seizures. Phenobarbital’s
popularity is likely to be due to its relative safety profiles,
as compared with phenytoin, and its ease of use and
traditional role.
Emerging evidence suggests that GABA receptor is
depolarizing early in development because of the peculiar
distribution of intracellular Cle concentration.9 Theoreti-
cally, if GABA receptor is exerting a depolarizing effect in
early stage brain development, GABAergic agents could
actually worsen neonatal seizures or at least not suppress
them effectively. Hence, for both neonatologists and
pediatric neurologists, there is an urgent need for study of
new antiepileptic drugs in neonates.Table 1 Common etiologies, age of onset, and prognosis
of neonatal seizures.
Etiologies Age of onset Prognosis
Hypoxic-ischemic encephalopathy 0e3 d Variable
Acute metabolica 3 d Favorable
Cerebrovascular 2 d Poor
Central nervous system infection 1e2 d Poor
Developmental defect  1 mo Poor
Epileptic syndrome
Benign neonatal convulsionsb 2e5 d Favorable
Severe epileptic syndromes 1e6 wk Poor
Modified from References 1 and 6.
a Most acute metabolic disturbances are hypoglycemia and
early-onset hypocalcemia.
b Benign idiopathic neonatal seizures and benign familial
neonatal seizures.GABA is excitatory initially and shapes the
developing brain circuits
The incidence of epilepsies is highest in human newborns
and neonatal animals. One candidate mechanism is the
developmental shift of the actions of GABA receptor.
Through the pioneer study in Ben-Ari’s team, the excitatory
nature of GABA receptor is recognized because of the
peculiar distribution of intracellular Cle concentration.9 In
the central nervous system, the intracellular Cle concen-
tration is regulated by the cation-chloride co-transporters.
In neonates, developmentally regulated early expression
of Naþ-Kþ-2Cle co-transporter 1 (NKCC1) and delayed
expression of Kþ-Cle co-transporter (KCC2) facilitates the
accumulation of Cle in neurons. Efflux of Cle leads to
depolarization of immature neurons rather than the
hyperpolarization observed in adults. The depolarization by
GABA of immature neurons is sufficient to generate Naþ
action potentials and to remove the voltage-dependent
Mg2þ blockade of N-methyl-D-aspartate (NMDA) receptors
and activate voltage-dependent Ca2þ channels, and is thus
excitatory in nature.
In all animal species, immature brain initially displays
a single primitive of giant depolarization potentials. Giant
depolarization potentials are dependent on both NMDA
and depolarizing GABA action,10 and are crucial for many
developmental processes including formation of synapses
and neuronal circuits.10 Giant depolarization potentials
mature in a caudal to rostral direction, i.e., at some point
during brain development, GABA is excitatory in the
brainstem but inhibitory in the cortex. This phenomenon
can be exemplified by the fact that phenobarbital can
suppress clinical motor seizure activity but not prevent
electrographic seizures from the brainstem.Increased seizure susceptibility in
developing brain
Experimental data implicate developmental changes in the
central nervous system’s major excitatory class of gluta-
mate neurotransmitter receptors and major inhibitory GABA
receptors as pivotal mechanisms that underlie the greater
susceptibility of the immature brain to seizures. Glutamate
exerts its direct postsynaptic effects primarily via three
classes of ionotropic glutamate receptor channel, including
NMDA, amino-3-hydroxy-5-methylisoxazole-4-propionic acid
(AMPA), and kainic acid receptors (KA), as well as metabo-
tropic glutamate receptors coupled to second messenger
systems.
In the immature brain, the predominant NR2 subunit is
the NMDA receptor 2B (NR2B) subunit, which functionally
results in slower decay time, decreased magnesium block,
and increased excitability, compared with the NR2A subunit,
which is highly expressed on mature neurons.11,12 AMPA
receptor subunits are also developmentally regulated, with
lower glutamate receptor 2 (GluR2) subunit expression and
thus higher calcium permeability. The low levels of GluR2
persists until the third postnatal week in rodents and later in
the first year of life in the human cortex.13 In summary, the
depolarizing effect of GABA, the overexpression of AMPA and
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the immature brain is at high risk for seizure occurrence.
In parallel, developing brain has delayed maturation
of the inhibitory system. Higher density of gap junctions
that may facilitate seizure spread.14 In addition, the major
postsynaptic inhibitory system, postsynaptic GABAB, aden-
osine, and 5-hydroxytryptamine-G protein coupled Kþ
channels also have a delayed maturation, suggesting that
the neonatal circuit operates without transmitter-gated
inhibition.15 These factors that cause increased seizure
susceptibility in developing brain are summarized and
depicted in Fig. 1.
Consequences of neonatal seizures
Lombroso argues that despite many high-quality studies in
neonatal animal models, there is still no convincing
evidence to support the view that neonatal seizures per se
plant the roots for epileptogenesis.16 The majority of
neonate seizures are symptomatic markers of underlying
brain pathologies or of metabolic derangements character-
istic of this period of brain development. In contrast, Miller
et al used H-magnetic resonance spectroscopy to evaluate
33 newborns with perinatal asphyxia with associated “clin-
ical seizures,” even if these were not corroborated by
concomitant discharges in their electroencephalogram.17
They found that seizure severity was independently associ-
ated with diminished N-acetylaspartate/choline in the
intervascular boundary zone and concluded that the
seizures were the cause of the brain injuries because of
impaired energy metabolism.
The outcome of prolonged neonatal seizures can include
consequences in later life including epilepsy (27%), cerebral
palsy, (20%), mental retardation (20%), and learning disor-
ders (27%).18 Recent studies of term infants with clinical
seizures showed a lower neonatal mortality of <20% as
a result of improvements in neonatal intensive care.6,18
Despite improved survival, however, the long-term neuro-
logic sequelae remain high and range from 28% to 46%.6,18Figure 1 Factors contributing to increased sIn animal studies, early-life seizures can result in
permanent neurological sequelae that appears to vary as
a function of age19,20 and functional status of the brain.21
Long-term adverse effects of neonatal seizures include
synaptic reorganization of axons and terminals of the den-
tate granule cells,22 alteration in glutamate23 and GABA
receptors,24 reduction in hippocampal neurogenensis25 and
seizure threshold,26 impaired single cell firing,27 and cogni-
tive deficits.27,28 Table 2 shows sequelae in human and
animal newborn studies.
Adverse effects of antiepileptic drugs (AEDs) in
developing brain
Inhibition of receptors during different stages of brain
development may also have consequences on brain devel-
opment, and AED may affect human intellect unfavorably.
Farwell et al treated young toddlers aged from 8 to 36
months with phenobarbital for febrile seizures and found
depressed cognitive performance after 2 years.29 An animal
study showed that phenobarbital administered in rat pups
results in significant decreases in brain weight.30 Using light
microscopy, immunofluorescence labeling, and western
blot, Bittigau et al demonstrated that traditional anticon-
vulsants, including phenytoin, phenobarbital, and val-
proate, may produce widespread apoptosis of neurons in
a variety of brain regions in developing rats at plasma
concentrations relevant for seizure control in humans.31
Similarly, a recent study has demonstrated that AEDs can
affect brain development by adversely affecting neuronal
migration and enhancing apoptosis.32 In contrast, thera-
peutic dosages of levetiracetam and topiramate did not
induce neurons apoptosis.33,34
Studies in neonatal rodents suggest that topiramate
and levetiracetam may be safer than the conventionally
used antiepileptic drugs (phenobarbital, phenytoin, and
benzodiazepines).33,34 Topiramate is a broad-spectrum
antiepileptic drug with several mechanisms of action
including: blockade of voltage-activated sodium channels;eizure propensity in the developing brain.
Table 2 Sequelae of neonatal seizure in human and animal studies.
Human Ref. Animal Ref.
Energy failure 17 Synaptic reorganization 22
Mortality 6,18 Alteration in glutamate and GABA receptors 23,24
Epilepsy 6,18 Reduction in hippocampal neurogenesis 25
Cerebral palsy 18 Reduction of seizure threshold 26
Mental retardation 18 Impaired single cell firing 27
Learning disorders 18 GABA receptors 27,28
242 L.-T. Huang et al.enhancement of GABA-mediated chloride flux; negative
modulatory effect on the AMPA/KA subtype of glutamate
receptors; attenuation of high-voltage-activated calcium
channels; and weak inhibition of carbonic anhydrase.35
Glier et al showed that topiramate had a favorable thera-
peutic index, and elicited a neurotoxic effect in infant rat
brain beginning at a dose of 50 mg/kg, which is higher than
the effective anticonvulsant doses in infant rodent seizure
models.33
Levetiracetam may bind synaptic vesicle protein SV2A
and modulate synaptic neurotransmitter release, and
possesses properties that distinguish it from other classical
AEDs.35 Manthey et al demonstrated a lack of neurotoxicity
of levetiracetam in the doses up to 100 mg/kg in immature
rats.34 Their findings are encouraging and suggest that
clinic trials of levetiracetam in infantile and early child-
hood seizure syndromes should be pursued. Clinically, only
a few reports described therapeutic use of levetiracetam in
infants with adequate seizure control and no adverse
effects.36e38
Translating experimental studies to clinical
practice
“Neurons that fire together, wire together” illustrates that
neuronal activity is crucial for normal brain development.
Neonatal seizures can modify the development of neuronal
circuits and construction of cortical maps, thereby
increasing the risk for subsequent seizures and adverse
outcome.39
GABA receptors still exert an inhibitory effect despite
being depolarizing during CNS development through another
mechanism: shunting.40 Shunting dissipates depolarizing
synaptic currents but below the threshold for action poten-
tial generation. Thus, when Cle is passively distributed
across the membrane, increasing Cle conductance will not
generate transmembranous Cle currents and no action
potential produced. Therefore, in clinical practice, pheno-
barbital still possesses capability to treat neonatal seizures.
Using immature rat intact hippocampal formation, Kha-
lilov et al demonstrated that seizures generated with
functional GABAergic synapses were required to transform
a naive network to an epileptic one.41 This finding could be
explained by the excitatory nature of GABA in the immature
brain. In addition, blocking GABA receptors prevented the
long-lasting sequelae of seizures, i.e., antiepileptogenesis.
Later, it was demonstrated that the combined activation of
functional GABA and glutamatergic synapses are needed to
generate high-frequency oscillations and the development
of chronic epileptogenesis.41,42Collectively, through different mechanisms, GABA
antagonist has ictogenic, anti-ictogenic, and antiepileptic
effects at one time in early postnatal brain development.
Hence, the effects of phenobarbital in the treatment of
neonatal seizures remain complex and controversial.
The AMPA-type glutamate receptor also plays a role in
neonatal seizures. Topiramate, an AMPA antagonist, is an
effective anticonvulsant and neuroprotectant in a rat
perinatal hypoxia-induced seizure model.43 AMPA receptor
antagonists such as NBQX and topiramate blocked acute
seizures and long-term sequelae in hypoxia-induced
seizures. In addition, topiramate plus hypothermia mark-
edly attenuates hypoxic-ischemic injury in a neonatal rat
stroke model.44
Bumetanide is used clinically as a loop diuretic including
in neonates. Dzhala et al used low-Mg2þ-induced epilepti-
form activity in the hippocampal slices and utilized
bumetanide to block NKCC1 function and prevent the
accumulation of intracellular Cle, thereby averting the
depolarizing action of GABAA receptor activation.
45 They
found that phenobarbital failed to abolish or depress
recurrent seizures in 70% of hippocampal slices. In contrast,
phenobarbital in combination with bumetanide abolished
seizures in 70% of hippocampal slices and significantly
reduced the frequency, duration, and power of seizures in
the remaining 30%. Furthermore, in genetically engineered
mice lacking NKCC1, bumetanide was not effective in
ameliorating seizures, supporting its role as a specific
inhibitor of NKCC1. Bumetanide is therefore a promising
drug with a mechanism-based treatment for neonatal
seizures.
There are significant limitations in extrapolating infor-
mation from animal studies to clinical practice. The studies
varied in animal species and age. Furthermore, the phar-
macokinetics and phamacodynamics of AEDs differ across
species. In most animal studies, neonatal seizures are
induced chemically in otherwise well animals. Conversely,
in human newborns, seizures are more commonly symp-
tomatic of an underlying brain insult. Indeed, the most
common etiology for neonatal seizures is hypoxic-ischemic
encephalopathy. Therefore, extrapolation the information
from the animals to humans must be cautious.Off-label use of AED in neonatal seizures
A recent survey conducted by pediatric neurologists in
2007, 73% (40/55) of them recommended treatment of
neonatal seizures with one or both of levetiracetam and
topiramate.46 Both drugs were typically recommended as
second, third, or subsequent agents.
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(FDA) for patients older than 2 years, while levetiracetam is
approved by FDA for those patients older than 4 years.
Although animal studies and anecdotal clinical reports show
promising results, topiramate or levetiracetam should be
used with caution until there are additional safety, phar-
macokinetic, and efficacy data from clinical trials.Conclusions
Despite substantial progress derived from animal studies to
suggest that neonatal seizures are harmful and phenobar-
bital has a controversial role, there has been little progress
in treatment in human neonatal seizures. Because it is
impractical to conduct a placebo-controlled trial with
a new anticonvulsant drug for human neonates, vigorous
electrograph and clinical monitoring and long-term follow-
up are needed to examine the prognosis of neonatal
seizures and to test add-on new drugs. Continuing dialogues
between the clinic and the bench will help resolve the
puzzles of neonatal seizures.Acknowledgments
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